Compare AAP & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAP | VCEL |
|---|---|---|
| Founded | 1929 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | N/A | 1997 |
| Metric | AAP | VCEL |
|---|---|---|
| Price | $47.75 | $37.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 19 | 5 |
| Target Price | $50.82 | ★ $57.50 |
| AVG Volume (30 Days) | ★ 2.0M | 518.5K |
| Earning Date | 02-13-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.14% | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $8,624,327,000.00 | $258,716,999.00 |
| Revenue This Year | N/A | $17.86 |
| Revenue Next Year | $1.01 | $18.55 |
| P/E Ratio | ★ N/A | $153.48 |
| Revenue Growth | N/A | ★ 14.05 |
| 52 Week Low | $28.89 | $29.24 |
| 52 Week High | $70.00 | $63.00 |
| Indicator | AAP | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 63.18 | 50.19 |
| Support Level | $39.92 | $35.85 |
| Resistance Level | $47.23 | $39.48 |
| Average True Range (ATR) | 2.09 | 1.89 |
| MACD | 0.96 | 0.00 |
| Stochastic Oscillator | 85.86 | 32.73 |
Advance Auto Parts is a leading auto-parts retailer in North America with more than 4,000 store and branch locations. About half of the firm's sales are geared toward the professional channel, with the remaining sales in the do-it-yourself market. Through its vast store footprint and distribution network, Advance manages thousands of stock-keeping units for various vehicle makes and models. The retailer primarily competes on the basis of inventory availability and service speed, making the operating efficiency of its hub-and-spoke distribution model critical to meeting customer needs.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.